More than 50% of adults and B20% of children with pre-B acute lymphoblastic leukemia (ALL) relapse following treatment. Dismal outcomes for patients with relapsed or refractory disease mandate novel approaches to therapy. We have previously shown that the combination of the mTOR inhibitor RAD001 (everolimus) and the chemotherapeutic agent vincristine increases the survival of non-obese diabetic/severe combined immuno-deficient (NOD/SCID) mice bearing human ALL xenografts. We have also shown that 16 mM RAD001 synergized with agents that cause DNA damage or microtubule disruption in pre-B ALL cells in vitro. Here, we demonstrate that RAD001 has dose-dependent effects on the cell cycle in ALL cells, with 1.5 mM RAD001 inhibiting pRb, Ki67 and PCNA expression and increasing G 0/1 cell cycle arrest, whereas 16 mM RAD001 increases pRb, cyclin D1, Ki67 and PCNA, with no evidence of an accumulation of cells in G 0/1 . Transition from G 2 into mitosis was promoted by 16 mM RAD001 with reduced phosphorylation of cdc2 in cells with 4 N DNA content. However, 16 mM RAD001 preferentially induced cell death in cells undergoing mitosis. When combined with vincristine, 16 mM RAD001 reduced the vincristine-induced accumulation of cells in mitosis, probably as a result of increased death in this population. Although 16 mM RAD001 weakly activated Chk1 and Chk2, it suppressed strong vincristine-induced activation of these cell cycle checkpoint regulators. We conclude that RAD001 enhances chemosensitivity at least in part through suppression of cell cycle checkpoint regulation in response to vincristine and increased progression from G 2 into mitosis.
INTRODUCTION
Although almost all children and 90% of adults with acute lymphoblastic leukemia (ALL) achieve a complete remission on current chemotherapy protocols, leukemic relapse remains a major problem. Approximately 20% of children and the majority of adults will relapse following the treatment [1] [2] [3] and the poor outcome following relapse has not significantly improved over the past two decades. 4, 5 The most rational approach to increasing overall survival is to increase the degree of initial leukemic cell death, thereby improving the quality of remissions and reducing relapse rates. It can be argued that outcomes with current pediatric chemotherapy protocols are reaching a plateau, suggesting that the addition of new agents is required. 1 An understanding of how novel agents interact with currently used chemotherapeutic agents will assist in making these decisions. mTOR inhibitors are currently in clinical trial for a range of hematological malignancies including ALL, mostly in combination with conventional chemotherapy. We recently reported that RAD001 (everolimus), an inhibitor of the mammalian target of rapamycin (mTOR), can synergize with a range of chemotherapeutic agents and ionizing radiation to increase apoptosis in ALL cells. 6 Others have also reported interactions between mTOR inhibitors and chemotherapeutic agents and some novel compounds. [7] [8] [9] [10] However, the mechanism underlying synergistic interactions is not understood. Cells undergo cell cycle arrest in response to a range of chemotherapeutic agents and this is thought to provide a degree of protection from the cytotoxic activity of these agents by providing the opportunity to repair DNA damage and maintain genomic integrity. 11, 12 A number of checkpoints have been documented including G 1 /S, intra-S, G 2 /M and the mitotic spindle cell cycle checkpoints. The DNA damage response is initiated by the PI3-kinase-like kinases ataxia telangiectasia mutated (ATM) and ataxia telangiectasia and Rad3 related (ATR) that control the G 1 /S, intra-S and G 2 /M checkpoints by activating the downstream effector kinases Chk2 and Chk1, respectively. 13 Although Chk2 is primarily activated by double-strand breaks, Chk1 is activated by a range of events including stalled replication forks, DNA crosslinks and ultraviolet radiation damage. Increasing cell cycle progression in the presence of chemotherapeutic agents may be a way to provide additional therapeutic benefit and provides a potential mechanism to explain the synergistic effects of RAD001 and chemotherapeutic agents on ALL cells.
In this study, we demonstrate that RAD001 has a dosedependent effect on cell cycle progression in ALL cells. Lower concentrations of RAD001 result in the well-documented cell cycle arrest in G 0/1 . 14,15 However, higher concentrations result in an accumulation of cells in S phase, primarily due to a specific loss of cells undergoing mitosis. In the presence of vincristine, 16 mM RAD001 suppressed activation of the DNA damage response and increased the proportion of cells committing to mitosis. This finding provides an explanation for the dose-dependent synergistic cell killing observed when RAD001 is added to cell cycle-dependent cytotoxic agents such as vincristine. These results indicate that favorable interactions between chemotherapeutic agents and RAD001 can occur, providing support for clinical trials where RAD001 is combined with chemotherapy for the treatment of relapsed ALL.
RESULTS

RAD001 induces dose-dependent changes in cell cycle distribution in ALL cells
We have previously reported that RAD001 treatment results in an accumulation of ALL cells in G 0/1 in vivo.
6 Consistent with this, RAD001 induced a dose-dependent inhibition of proliferation in ALL cell lines as assessed by 3 H-thymidine incorporation (Figure 1a) . However, further analysis of the effects of RAD001 on ALL cells revealed contrasting dose-dependent effects on cell cycle. Lower concentrations (1.5 mM) of RAD001 resulted in the expected accumulation of cells in G 0/1 (Figure 1b ) and were associated with reduced phosphorylation of the retinoblastoma protein (Rb), and reduced expression of Ki67 and PCNA as expected (Figures 1c and d) . In contrast, 16 mM RAD001 paradoxically increased the proportion of cells in S phase in association with increased phosphorylation of Rb ( Figure 1c ) and increased expression of cyclin D1 (Supplementary Figure S1 ), Ki67 and PCNA (Figure 1d ). This suggests that cell cycle regulation by RAD001 is dose-dependent and that 16 mM RAD001 has the potential to facilitate transition from G 1 to S phase of the cell cycle. As illustrated in Figure 1a , this apparent increase in transition into S phase did not translate into increased proliferation as assessed by 3 H-thymidine incorporation.
We have previously shown that 16 mM RAD001 results in cell death. 16 Here, we show that 16 mM RAD001 reduces viable cell recovery (Figure 2a ) and the number of cell divisions successfully completed (Figure 2b ), suggesting that cells are dying while attempting to cycle. Chk1 and Chk2 are the principal factors responsible for initiating cell cycle checkpoints, and are activated by phosphorylation on serine and threonine residues, including (Figures 3f and g ).
Direct measurement of cell viability in the total population, and BrdU þ and BrdU À fractions also supported a preferential loss of cells treated with 16 mM RAD001 during G 2 /M (Figures 3h-j) . The BrdU þ fraction had measurable cell death by 10 h (Figure 3i ), whereas in the BrdU À fraction this was not apparent until 14 h (Figure 3j ) coinciding with the entry of cells into G 2 /M (Figure 3g ). Overall, this demonstrates that 1.5 mM RAD001 induces a cell cycle arrest in G 0/1 with little impact on other measures of the cell cycle, whereas 16 mM RAD001 encourages cell cycle progression but induces cell death in cycling cells, particularly those in G 2 /M.
To further examine what was occurring in the G 2 /M phase of the cell cycle, we used staining for phosphorylated histone-H3 on Ser 10 to distinguish mitotic cells from those in G 2 , which lack phosphorylation of histone-H3. In cultures treated with 16 mM RAD001 the proportion of cells in G 2 /M expressing phosphorylated histone-H3 was reduced (Figure 4c ), consistent with death during or before mitosis. In contrast, the proportion of cells where cdc2 was dephosphorylated on Tyr 15 , a requirement for entry into mitosis, was elevated (Figure 4d ), demonstrating that commitment to mitosis was still occurring and that 16 mM RAD001 was promoting the transition from G 2 to mitosis. This demonstrates that death is occurring after commitment to mitosis has occurred. Therefore, 16 mM RAD001 induces changes in cell cycle regulators that promote transition from G 2 to mitosis, but results in the preferential death of actively cycling cells, which predominantly occurs during mitosis.
The vincristine-induced accumulation of mitotic cells is reduced by 16 mM RAD001 We have previously reported that RAD001 synergizes with chemotherapeutic agents. 16 Vincristine is a microtubule poison that results in failed mitosis and ultimately cell death. It is therefore possible that the changes in cell cycle regulation induced by 16 mM RAD001 enhance vincristine-induced cell death. Using standard analysis of cell cycle distribution vincristine was found to induce the accumulation of cells in G 2 /M, although this was perhaps not as marked as expected (Supplementary Figure  S2) . 11 To examine this more closely, staining for phosphorylated histone-H3 was used to identify mitotic cells. This method clearly revealed the expected accumulation of cells arrested in mitosis in (Figure 5b ). These studies also demonstrated that cells in mitosis with phosphorylated histone-H3 had lower than expected DNA content following vincristine treatment (Figure 5a ), making standard cell cycle analysis using DNA content unreliable in this setting. To examine these effects in a more synchronized population of cells, we used a BrdU pulse to track cells in S phase at the time of drug addition. This further confirmed the accumulation of mitotic cells in response to vincristine. As expected, 16 mM RAD001 significantly reduced the number of cells arrested in mitosis (Figure 5c ), whereas 1.5 mM RAD001 had only a limited effect. This could result from the induction of death in mitotic cells by vincristine and/or 16 mM RAD001 or by the failure of cells to reach mitosis. To confirm that cells exposed to 16 mM RAD001 were reaching mitosis the dephosphorylation of cdc2 was assessed in the BrdU þ fraction. Interestingly, the addition of 16 mM RAD001 dramatically increased the commitment to mitosis (Figure 5d ). This effect peaked 14 h after the addition of drugs and then declined by 18 h. This is consistent with the passage of cells that were in S phase at the start of culture through G 2 , committing to (phosphorylated cdc2 low) and undergoing mitosis (phosphorylated histone-H3 positive) where cell death occurs.
RAD001 suppresses vincristine-induced cell cycle checkpoint activation As mentioned above, activation of cell cycle checkpoint regulators such as Chk1 and Chk2 has a critical role in promoting cell cycle arrest in response to cytotoxic agents. Although 16 mM RAD001 alone induced phosphorylation of Chk1 and Chk2, this was a relatively modest effect when compared with that of vincristine (Figures 6a and b) . Again using a BrdU pulse to track a more synchronized cell population, RAD001 was found to produce a dose-dependent decrease in the vincristine-induced activation of both Chk1 and Chk2 in the BrdU þ population (Figures 6c and d) . Interestingly, 1.5 mM RAD001, which had only a marginal effect on cell cycle progression from S phase through mitosis and back to G 0/1 , (Figure 3 ) had a significant inhibitory effect on the activation of Chk1 and Chk2 (Figures 6c-e) . This demonstrates that RAD001 inhibits the vincristine-induced activation of the DNA damage response and cell cycle checkpoint regulators.
DISCUSSION
Rapamycin is reported to inhibit the transition from G 1 to S phase 18 by disruption of cyclin D1/cdk2 complexes resulting in an accumulation of cells in G 0/1 . 19, 20 Here, we demonstrate that another mTOR inhibitor, RAD001, induces dose-dependent changes in cell cycle distribution in pre-B ALL cells. Although lower concentrations mediate the anticipated delay in G 0/1 , higher concentrations result in an increase in the proportion of cells in S phase with a reduction in the G 0/1 and G 2 /M components. The decreased proportion of cells in G 0/1 and G 2 /M was consistent with changes in PCNA, Ki67 and pRb in G 0/1 , and PCNA and phosphorylated histone-H3 in G 2 /M. However, the apparent increase in the proportion of S phase cells was at least partially due to the selective death of cells undergoing mitosis. Despite some activation of the cell cycle checkpoint regulators Chk1 and Chk2, there was no evidence of an S phase arrest or delay. An increase in the proportion of cells committed to mitosis was apparent despite the overall reduction in the G 2 /M fraction, suggesting that 16 mM RAD001 was promoting transition from the G 2 phase of the cell cycle to mitosis, facilitating enhanced killing by cell cycle-specific agent vincristine.
Careful cell cycle tracking, using BrdU to mark cells in S phase, showed that 1.5 mM RAD001 did not impact on cell cycle progression until the cells had returned to G 0/1 , where it inhibited entry into a second cell cycle. Inhibition of mTOR is well documented to result in a G 0/1 cell cycle arrest in many cell types. [21] [22] [23] This inhibition was independent of cell cycle checkpoint regulation, with no measurable activation of Chk1 or Chk2 (data not shown). In contrast, the effect of 16 mM RAD001 on the accumulation of cells in S phase was not associated with a measurable delay in cells exiting S phase, despite a small but measurable activation of Chk1 and Chk2 in cells entering S phase. 17, 24 It is reasonable to consider that S phase checkpoint activation and subsequent S phase delay may be balanced by the death of a proportion of cells in S phase.
The premature entry into mitosis induced by higher doses of RAD001 is reminiscent of results reported in fission yeast, where inhibition of TOR by rapamycin or nutrient deprivation resulted in mitosis occurring at an earlier time point and a smaller cell size. Similar to our findings this was associated with activation of maturation-promoting factor, the yeast equivalent to the cdc2/ cyclin-B complex, by dephosphorylation of cdc2. 25 Related studies in Drosophila found an increase in the proportion of mitotic cells as determined by the phosphophorylation of histone-H3. 26 However, this contrasts with our findings where, despite increased commitment to mitosis, fewer mitotic cells were present. The only reasonable explanation for this is that these cells are dying via non-apoptotic means.
Vincristine and other agents that disrupt microtubule function can induce cell cycle arrest in G 0/1 and G 2 /M, which can protect cells from the cytotoxic effects of these agents. 11, 27 Vincristine alone clearly induced the accumulation of mitotic cells, some of which could be expected to eventually complete mitosis, although this may be with additional cytogenetic defects as a result of abnormal spindle formation. Although the mitotic checkpoint, which senses the correct attachment of chromosomes to the mitotic spindle, 28 was likely activated in these cells, a strong activation of Chk1 and Chk2 was also apparent. 29 The addition of 16 mM RAD001 resulted in a dramatic reduction in the activation of these checkpoint regulators. There are a number of possible reasons why RAD001 prevented the phosphorylation of the cell cycle checkpoint proteins. First mTOR directly suppresses the activity of the phosphatase PP2A 30 that dephosphorylates and inactivates cell cycle checkpoint proteins including Chk1 and Chk2. 31 However, inhibitors of PP2A did not consistently restore the phosphorylation of these proteins (data not shown). Second, mTOR activates p53, 32 which in turn can activate cell cycle checkpoints, and we have previously shown that RAD001 prevents vincristine-induced induction of p53. 16 Finally, mTOR activates aurora-B, 33 which also activates cell cycle checkpoints including the spindle checkpoint. 34 Overall, the suppression of checkpoint activation, together with the increased proportion of cells committed to mitosis, suggests that in the presence of 16 mM RAD001 cell cycle progression from G 2 to mitosis is likely to be increased. This provides an explanation for the synergistic effects seen when 16 mM RAD001 is combined with vincristine. It is likely that this combination would result in the induction of mitotic catastrophe, consistent with our previous report that cell death resulting from the combination of RAD001 and chemotherapy is apoptotic and is independent of p53. 16, 35 A dose escalation study of RAD001 in combination with standard chemotherapy, including vincristine, in adult patients with relapsed ALL is currently underway. Although it is unlikely that micro-molar plasma concentration of RAD001 can be achieved in vivo, preclinical studies have demonstrated in vivo efficacy at considerably lower plasma concentrations. An explanation for this discrepancy has not come to light and the potential for elevated location concentrations within crucial micro-environmental niches remains a possibility.
In conclusion, we have shown that RAD001 induces dosedependent changes in cell cycle distribution in pre-B ALL cells. Concentrations of RAD001 that synergize with chemotherapeutic agents, including vincristine, promote transition from G 2 to mitosis and dampen the activation of the checkpoint regulators Chk1 and Chk2 in the presence of chemotherapy. Of particular interest is the effect on cdc2 at the G 2 /M transition, as this effect is only observed with higher concentrations of RAD001 associated with synergistic interactions. This provides a tantalizing clue as to why higher concentrations of RAD001 interact synergistically with chemotherapeutic agents such as vincristine. It is reasonable to consider that by promoting entry into mitosis RAD001 facilitates the actions of agents that act on mitotic cells. 
MATERIALS AND METHODS Cells
Human precursor-B ALL cell lines were obtained as follows: NALM6 from Deutsche Sammlung Von Mikroorganismen und Zellkulturen Gmbh (DSMZ, Braunschweig, Germany); Reh from American Type Culture Collection, ATCC (Manassas, VA, USA); and LK63 was a gift from Professor Andrew Boyd (Queensland Institute of Medical Research, Brisbane, QLD, Australia). Cells were maintained in RPMI medium containing 10% fetal calf serum (complete media) as previously described. 36, 37 Cells were not cultured for 46 months. The ATCC and DSMZ verify cell lines using short tandem repeat loci. LK63 cells were verified by immunophenotyping.
Antibodies and reagents RAD001 (everolimus) was kindly provided by Novartis (Basel, Switzerland). Vincristine sulphate was purchased from Millennium Pharmaceuticals (Cambridge, MA, USA) or Pfizer (Melrose Park, NSW, Australia). Ionizing radiation was delivered using an X-ray irradiator (XRAD320, Precision X-ray, 
Proliferation assays
Proliferation assays were performed by 3 H-thymidine (NET027Z005MC, PerkinElmer, Melbourne, VIC, Australia) incorporation as previously described. 38 Briefly, 3 H-thymidine (1 mCi) was added after 72 h of culture and cells collected onto glass fiber filters (PerkinElmer, 6005412) after another 16 h of culture. Radioactivity was measured using a Topcount NXT scintillation counter after addition of 30 ml of Microscint 40 per well.
Cells were labeled with 2 mM carboxy-fluorescein diacetate succinimidyl ester (Invitrogen, C1157) in RPMI containing 0.5% fetal calf serum for 10 min at room temperature and washed twice in ice-cold RPMI. Cells were then incubated for 6 h in RPMI containing 20% fetal calf serum and washed again before plating. Cells were then plated at 2.5 Â 10 5 /ml and incubated for 72 h. The number of cell divisions determined by flow cytometry and was analyzed using ModFit software (Verity Software House, Topsham, ME, USA). 
